Extracellular Matrix for Small-Diameter Vascular Grafts

Tissue Eng Part A. 2020 Dec;26(23-24):1388-1401. doi: 10.1089/ten.TEA.2020.0201.

Abstract

To treat coronary heart disease, coronary artery bypass grafts are used to divert blood flow around blockages in the coronary arteries. Autologous grafts are the gold standard of care, but they are characterized by their lack of availability, low quality, and high failure rates. Alternatively, tissue-engineered small-diameter vascular grafts made from synthetic or natural polymers have not demonstrated adequate results to replace autologous grafts; synthetic grafts result in a loss of patency due to thrombosis and intimal hyperplasia, whereas scaffolds from natural polymers are generally unable to support the physiological conditions. Extracellular matrix (ECM) from a variety of sources, including cell-derived, 2D, and cannular tissues, has become an increasingly useful tool for this application. The current review examines the ECM-based methods that have recently been investigated in the field and comments on their viability for clinical applications.

Keywords: coronary artery bypass graft; decellularized; extracellular matrix; small-diameter vascular grafts.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Autografts
  • Bioprosthesis*
  • Blood Vessel Prosthesis*
  • Extracellular Matrix
  • Vascular Patency